Opus Genetics Inc (IRD)

$1.13 -0.03 (-2.59%)
Market Cap 35.67M
Revenue (ttm) 19.05M
Net Income (ttm) -9.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -52.44%
Debt to Equity Ratio 0.00
Volume 53,300
Avg Vol 245,572
Day's Range N/A - N/A
Shares Out 31.57M
Stochastic %K 2%
Beta 0.16
Analysts Strong Sell
Price Target $11.00

Latest News on IRD

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Dec 19, 2024, 8:00 AM EST - 4 weeks ago

Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2024, 7:59 AM EST - 2 months ago

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)